Caroline Junqueira obtained her Master’s degree in Biochemistry and her PhD in Immunology, both at Federal University of Minas Gerais (Brazil). During her PhD, Dr. Junqueira developed a cancer vaccine, employing Trypanosoma cruzi as a vector. Her thesis was awarded by the Brazilian Federal Government as the best PhD thesis defended in Brazil in 2012. She worked for a few years in the United States at Memorial Sloan Kettering Cancer Center and University of Notre Dame, before starting her own lab at Oswaldo Cruz Foundation (Brazil). From 2017 to 2023, she divided her time between Brazil and Harvard Medical School, and in the summer of 2023, she will join the IRB as a Group Leader. In 2019, she was elected an Affiliate Member to the Brazilian Academy of Sciences.